These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. Carter HB; Pearson JD; Metter EJ; Brant LJ; Chan DW; Andres R; Fozard JL; Walsh PC JAMA; 1992 Apr 22-29; 267(16):2215-20. PubMed ID: 1372942 [TBL] [Abstract][Full Text] [Related]
4. The effects of transurethral prostatectomy on serum prostate specific antigen. Vesey SG; Goble NM; Stower MJ; Hammonds JC; Smith PJ Br J Urol; 1988 Oct; 62(4):347-51. PubMed ID: 2461243 [TBL] [Abstract][Full Text] [Related]
5. Evaluation and characterization of anti-RalA autoantibody as a potential serum biomarker in human prostate cancer. Li J; Dai L; Lei N; Xing M; Li P; Luo C; Casiano CA; Zhang JY Oncotarget; 2016 Jul; 7(28):43546-43556. PubMed ID: 27286458 [TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen (PSA). A tissue-specific and sensitive tumor marker. Mulders TM; Bruning PF; Bonfrer JM Eur J Surg Oncol; 1990 Feb; 16(1):37-41. PubMed ID: 1689677 [TBL] [Abstract][Full Text] [Related]
7. Prostate specific antigen. A review. Brawer MK Acta Oncol; 1991; 30(2):161-8. PubMed ID: 1709355 [TBL] [Abstract][Full Text] [Related]
8. Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. Carter HB; Morrell CH; Pearson JD; Brant LJ; Plato CC; Metter EJ; Chan DW; Fozard JL; Walsh PC Cancer Res; 1992 Jun; 52(12):3323-8. PubMed ID: 1375867 [TBL] [Abstract][Full Text] [Related]
9. Quantification of prostatic cancer metastatic disease using prostate-specific antigen. Vesey SG; Goble M; Ferro MA; Stower MJ; Hammonds JC; Smith PJ Urology; 1990 Jun; 35(6):483-6. PubMed ID: 1693796 [TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen in prostatic cancer. Baron JC; Peyret C; Leroy M; Teillac P; Najean Y; Le Duc A Am J Clin Oncol; 1988; 11 Suppl 2():S75-6. PubMed ID: 2468279 [TBL] [Abstract][Full Text] [Related]
11. The value of the measurement of serum prostate specific antigen in patients with benign prostatic hyperplasia and untreated prostate cancer. Armitage TG; Cooper EH; Newling DW; Robinson MR; Appleyard I Br J Urol; 1988 Dec; 62(6):584-9. PubMed ID: 2464397 [TBL] [Abstract][Full Text] [Related]
12. [Prostate-specific antigen. A new biological serum marker for prostatic adenocarcinoma]. Haukaas S; Skaarland E; Halvorsen OJ; Stensland E; Farstad M Tidsskr Nor Laegeforen; 1990 Sep; 110(23):2990-3. PubMed ID: 1700496 [TBL] [Abstract][Full Text] [Related]
13. [The value of the serum level of the prostate-specific antigen in prostatic pathology]. Théodon P; Rymer JC; Chopin D; Kouyoudjian JC; Abbou CC; Auvert J Ann Urol (Paris); 1988; 22(3):199-205. PubMed ID: 2456713 [TBL] [Abstract][Full Text] [Related]
14. Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia. Haese A; Graefen M; Noldus J; Hammerer P; Huland E; Huland H J Urol; 1997 Dec; 158(6):2188-92. PubMed ID: 9366341 [TBL] [Abstract][Full Text] [Related]
15. Clinical evaluation of a new prostate-specific antigen sandwich ELISA which employs four monoclonal antibodies directed at different epitopes of prostate-specific antigen. Jurincic-Winkler C; von der Kammer H; Horlbeck R; Klippel KF; Pixberg HU; Scheit KH Eur Urol; 1993; 24(4):487-91. PubMed ID: 7507048 [TBL] [Abstract][Full Text] [Related]
16. Volume of normal prostate, of prostate cancer, and of benign prostatic hyperplasia: are correlations with prostate specific antigen clinically useful? Clements R; Penney MD; Etherington RJ; Griffiths GJ; Hughes H; Peeling WB Prostate Suppl; 1992; 4():51-7. PubMed ID: 1374178 [TBL] [Abstract][Full Text] [Related]
17. [Prostate-specific antigen in prostatic pathology]. Teillac P; Peyret C; Leroy M; Najean Y; Le Duc A Ann Urol (Paris); 1988; 22(3):193-6. PubMed ID: 2456712 [TBL] [Abstract][Full Text] [Related]
18. Immunocytochemical evaluation of human prostatic carcinomas for carcinoembryonic antigen, nonspecific cross-reacting antigen, beta-chorionic gonadotrophin, and prostate-specific antigen. Purnell DM; Heatfield BM; Trump BF Cancer Res; 1984 Jan; 44(1):285-92. PubMed ID: 6197163 [TBL] [Abstract][Full Text] [Related]
19. A multicenter clinical trial on the use of alpha1-antichymotrypsin-prostate-specific antigen in prostate cancer diagnosis. Lein M; Jung K; Hammerer P; Graefen M; Semjonow A; Stieber P; Ossendorf M; Luboldt HJ; Brux B; Stephan C; Schnorr D; Loening SA Prostate; 2001 May; 47(2):77-84. PubMed ID: 11340629 [TBL] [Abstract][Full Text] [Related]
20. Tumour markers in prostatic carcinoma. A comparison of prostate-specific antigen with acid phosphatase. Ferro MA; Barnes I; Roberts JB; Smith PJ Br J Urol; 1987 Jul; 60(1):69-73. PubMed ID: 2441790 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]